Minireview
Application of Positron Emission Tomography for Evaluation of Metabolism and Blood Flow in Human Brain: Normal Development, Aging, Dementia, and Stroke

https://doi.org/10.1006/mgme.2001.3236Get rights and content

First page preview

First page preview
Click to open first page preview

References (67)

  • ME Phelps et al.

    Tomographic measurement of local cerebral glucose metabolic rate in humans with (F-18)2-fluoro-2-deoxyglucose: Validation of method

    Ann Neurol

    (1979)
  • N Reivich et al.

    The [18F]fluorodeoxyglucose method for the measurement of local cerebral glucose utilization in man

    Circ Res

    (1979)
  • S Minoshima et al.

    Interpretation of metabolic abnormalities in Alzheimer's disease using three-dimensional stereotactic surface projections (3D-SSP) and normal database

    J Nuclear Medicine.

    (1995)
  • JR Moeller et al.

    The metabolic topography of normal aging

    J Cereb Blood Flow Metabolism

    (1996)
  • K Ishii et al.

    Cerebral glucose metabolism in patients with frontotemporal dementia

    J Nucl Med

    (1998)
  • I Law et al.

    Quantitation of regional cerebral blood flow corrected for partial volume effect using O-15 water and PET: II. Normal values and gray matter blood flow response to visual activation

    J Cereb Blood Flow Metabolism

    (2000)
  • SC Huang et al.

    Quantitative measurement of local cerebral blood flow in humans by positron computed tomography and 15O-water

    J Cereb Blood Flow Metab

    (1983)
  • CC Meltzer et al.

    Does cerebral blood flow decline in healthy aging?. A PET study with partial-volume correction

    J Nucl Med

    (2000)
  • HT Chugani et al.

    Maturational changes in cerebral function in infants determined by 18FDG positron emission tomography

    Science

    (1986)
  • HT Chugani et al.

    Positron emission tomography study of human brain functional development

    Ann Neurol

    (1987)
  • T Takahashi et al.

    Developmental changes of cerebral blood flow and oxygen metabolism in children

    AJNR

    (1999)
  • DC Chugani et al.

    Developmental changes in brain serotonin synthesis capacity in autistic and nonautistic children

    Ann Neurol

    (1999)
  • SK Schultz et al.

    Age-related changes in regional cerebral blood flow among young to mid-life adults

    NeuroReport

    (1999)
  • JC Mazziotta et al.

    Positron emission tomography studies of the Brain

  • DA Evans

    Estimated prevalence of Alzheimer's disease in the US

    Milbank Q

    (1990)
  • RL Ernst et al.

    The U. S. economic and social costs of Alzheimer's disease revisited

    Am J Public Health

    (1994)
  • National Institute of Aging, Progress report on Alzheimer's disease. NIH publication No. 96-4137. 1996, Bethesda, MD,...
  • MY Zhang et al.

    The prevalence of dementia and Alzheimer's disease in Shanghai, China: Impact of age, gender, and education

    Ann Neurol

    (1990)
  • R Katzman

    Education and the prevalence of dementia and Alzheimer's disease

    Neurology

    (1993)
  • Y Stern et al.

    Inverse relationship between education and parietotemporal perfusion deficit in Alzheimer's disease

    Ann Neurol

    (1992)
  • Y Stern et al.

    Relationship between lifetime occupation and parietal flow: Implications for a reserve against Alzheimer's disease pathology

    Neurology

    (1995)
  • GE Alexander et al.

    Association of premorbid intellectual function with cerebral metabolism in Alzheimer's disease: Implications for the cognitive reserve hypothesis

    Am J Psychiatry

    (1997)
  • DA Evans et al.

    Apolipoprotein E epsilon-4 and incidence of Alzheimer disease in a community population of older persons

    J Am Med Assoc

    (1997)
  • Cited by (33)

    • Right Broca's area is hyperactive in right-handed subjects during meditation: Possible clinical implications?

      2021, Medical Hypotheses
      Citation Excerpt :

      The subjects were in fasting state for at least 3 h prior to the scanning procedure. After image reconstruction, a region of interest (ROI) was quantified with the help of ‘NeuroQ’ software Version 3.0 (University of California, Los Angeles), which aids in assessment of human brain scans through quantification of mean pixels values lying within standardized region of interest (ROI) [27–30]. The specific areas in brain which were hyperactive during meditation using 18FDG-PET have been published previously [24].

    • Amyloid imaging: Past, present and future perspectives

      2016, Ageing Research Reviews
      Citation Excerpt :

      The insight into the molecular mechanism of AD pathogenesis opened new avenues for the successful development of new neuroimaging approaches. ( Selkoe, 2000) Modern functional neuroimaging techniques such as positron emission tomography (PET), tend to be more sensitive than structural imaging modalities, identifying subtle pathophysiologic changes in the brain, before structural changes are present (Bobinski et al., 1999; de Leon et al., 1997; De Toledo-Morrell et al., 2000; Dickerson et al., 2001; Juottonen et al., 1998; Killiany et al., 2000; Xu et al., 2000), therefore possessing greater potential for accurate and early diagnosis, monitoring disease progression, and better treatment follow-up (Silverman and Phelps, 2001; Villemagne et al., 2005). PET is a sensitive molecular imaging technique that allows in vivo quantification of radiotracer concentrations in the picomolar range, where either the radiotracer bears the same biochemical structure, is an analog or a substrate of the chemical process being evaluated, allowing the in vivo assessment of the molecular process at their sites of action, (Phelps, 2000) permitting detection of disease processes at asymptomatic stages when there is no evidence of anatomic changes on CT and MRI.

    • Emerging trends in in vivo neurochemical monitoring by microdialysis

      2013, Current Opinion in Chemical Biology
      Citation Excerpt :

      Therefore analytical measurements must be compatible with ‘samples on legs’. Several techniques have been developed that allow in vivo neurotransmitter measurement including positron emission tomography (for reviews see [5–8]), cell based sensors [9], fluorescent tracers [10], implantable electrochemical sensors [11–15], and microdialysis sampling [16,17]). Although exciting advances have been made in all these areas recently, we will restrict our review to microdialysis sampling.

    • Carotid Artery Ultrasound and Echocardiography Testing to Lower the Prevalence of Alzheimer's Disease

      2009, Journal of Stroke and Cerebrovascular Diseases
      Citation Excerpt :

      Brain hypoperfusion may be present even before any cognitive symptoms appear. For example, it is well accepted that within a vascular territory, cerebral blood flow (CBF) is coupled to glucose uptake and both measures are practically linear.68 When 18fluoro-2-deoxy-D-glucose-positron emission tomography scans of cognitively healthy elderly individuals were analyzed, reduced glucose uptake in the hippocampus, a brain region linked to short-term memory, allowed significant prediction of which individuals would later convert to AD.69

    • Chapter 3 Cerebrovascular and Cardiovascular Pathology in Alzheimer's Disease

      2009, International Review of Neurobiology
      Citation Excerpt :

      Individuals at risk of AD but who do not express any cognitive deficits show local hypometabolic reductions of the cerebral metabolic rate of glucose after FDG in brain regions that will later develop atrophy and neurodegeneration (de Leon et al., 2001). Since measures of glucose metabolic rate and CBF are coupled (Silverman and Phelps, 2001), FDG‐PET studies are proof of concept that regional brain hypoperfusion precedes Alzheimer clinical symptoms, Aβ production, and neurodegenerative changes. FDG‐PET can also track AD progression (de Leon et al., 2001).

    View all citing articles on Scopus

    Supported by funds from the United States Department of Energy, Contract No. DE-FCO3-87ER60615, and the Los Angeles Alzheimer's Association, Turken Family Foundation Award.

    2

    To whom correspondence should be addressed at University of California, Los Angeles, School of Medicine, Ahmanson Biological Imaging Center, CHS AR-144, MC694215, Los Angeles, CA 90095-6942. E-mail: [email protected].

    View full text